Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities of marketable securities | 81,711 | 32,445 |
| Proceeds from sale of fixed assets | 8 | 2 |
| Purchase of marketable securities | (10,011) | — |
| Purchases of fixed assets | (5,202) | (4,718) |
| Acquisition of businesses, net of cash | (55,567) | — |
| Net cash provided by investing activities | 10,939 | 27,729 |
| Cash flow from financing activities: | ||
| Repurchase of common stock | (40,078) | (8,679) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s capex?
- Fulgent Genetics, Inc. (FLGT) reported capex of $5.2M in Q1 2026.
- How has Fulgent Genetics, Inc.'s capex changed year-over-year?
- Fulgent Genetics, Inc.'s capex increased by 10.3% year-over-year, from $4.72M to $5.2M.
- What is the long-term trend for Fulgent Genetics, Inc.'s capex?
- Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s capex has grown at a -1.3% compound annual growth rate (CAGR), from $23.81M to $22.57M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Fulgent Genetics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude